Literature DB >> 18690092

9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.

Simin Dadashzadeh1, Katayoun Derakhshandeh, Farshad Hoseini Shirazi.   

Abstract

The objective of this study was to evaluate the cytotoxicity and pharmacokinetics of total and lactone forms of 9-nitrocamptothecin (9-NC), an effective antineoplastic drug, after intravenous injection of drug incorporated into poly (DL-lactic-glycolic acid) nanoparticles (NPs). Drug-loaded NPs (9-NC.NP) were prepared by the nanoprecipitation method and examined for particle characteristics and in-vitro release in phosphate buffered saline. The best formulation showed a narrow size with an average diameter of 207+/-26 nm and a drug loading of more than 33.5%. The drug release profile showed a sustained 9-NC release up to 160 h. For a pharmacokinetic study, the concentration of 9-NC as the lactone form (9-NC.lac) and as the total of the lactone and carboxylate forms (9-NC.tot) in plasma was determined by using reverse-phase high performance liquid chromatography after intravenous administration of 9-NC.NP and a control solution to cannulated Wistar rats. In-vitro cytotoxic activity of 9-NC.NP and control solution was evaluated on the human ovarian cancer cell line (A2780sn) by MTT cell cytotoxicity assay. Results of in-vivo studies showed that NP encapsulation markedly increased the plasma concentration of both lactone and total forms of 9-NC compared with free drug. In comparison with free drug, NPs resulted in 3.63-fold and 5.40-fold increases in area under the plasma concentration-versus-time curve (AUC(0-infinity)) for lactone and total forms of 9-NC, respectively. The values of mean residence time and elimination half-life (T(1/2)) were also significantly higher for NPs than for free drug. The in-vitro cytotoxicity study revealed that the IC50 value of NPs decreased 10-fold compared with the drug solution. Prepared NPs described here were considered potentially useful in both stabilizing and delivering 9-NC and enhancing the efficacy of this drug for cancer treatment for which high drug retention in the body, protection from the drug-active lactone form, and gradual drug release appeared to be related.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690092     DOI: 10.1097/CAD.0b013e3283099e5c

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  11 in total

1.  Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Authors:  Rajendra S Kadam; David W A Bourne; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-04-12       Impact factor: 3.922

2.  Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation.

Authors:  Deepak Chitkara; Anupama Mittal; Ram I Mahato; Neeraj Kumar
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

3.  Orcinol Glucoside Loaded Polymer - Lipid Hybrid Nanostructured Lipid Carriers: Potential Cytotoxic Agents against Gastric, Colon and Hepatoma Carcinoma Cell Lines.

Authors:  Prasant Nahak; Rahul L Gajbhiye; Gourab Karmakar; Pritam Guha; Biplab Roy; Shila Elizabeth Besra; Alexey G Bikov; Alexander V Akentiev; Boris A Noskov; Kaushik Nag; Parasuraman Jaisankar; Amiya Kumar Panda
Journal:  Pharm Res       Date:  2018-08-27       Impact factor: 4.200

Review 4.  Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

Authors:  Vincent J Venditto; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

5.  New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell.

Authors:  Soheila Kashanian; Abbas Hemati Azandaryani; Katayoun Derakhshandeh
Journal:  Int J Nanomedicine       Date:  2011-11-01

6.  Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells.

Authors:  Simona Mura; Herve Hillaireau; Julien Nicolas; Benjamin Le Droumaguet; Claire Gueutin; Sandrine Zanna; Nicolas Tsapis; Elias Fattal
Journal:  Int J Nanomedicine       Date:  2011-10-26

7.  Encapsulation in PLGA-PEG enhances 9- nitro-camptothecin cytotoxicity to human ovarian carcinoma cell line through apoptosis pathway.

Authors:  F Ahmadi; K Derakhshandeh; A Jalalizadeh; A Mostafaie; L Hosseinzadeh
Journal:  Res Pharm Sci       Date:  2015 Mar-Apr

8.  In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer Model.

Authors:  Katayoun Derakhshandeh; Gunther Hochhaus; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

9.  Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat.

Authors:  Katayoun Derakhshandeh; Moin Karimi; Abbas Hemati Azandaryani; Gholamreza Bahrami; Kiumras Ghanbari
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

10.  Active targeted nanoparticles: Preparation, physicochemical characterization and in vitro cytotoxicity effect.

Authors:  Sh Heidarian; K Derakhshandeh; H Adibi; L Hosseinzadeh
Journal:  Res Pharm Sci       Date:  2015 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.